Better Health. Better Life.

M Pharmaceutical Inc. Clarifies Timing for Ten for One Share Consolidation

Vancouver, B.C., Canada – M Pharmaceutical Inc. (the "Company") (CSE:MQ), clarified today the timing of its previously announced consolidation (the "Consolidation") of its issued and outstanding common shares ("Common Shares") on the basis of ten old Common Shares for one new Common Share. The proposed Consolidation was approved by shareholders at a special meeting of the Company held on October 10, 2014 and is subject to the approval of the Canadian Securities Exchange ("CSE").  Following the Consolidation, the Company will have approximately 14,273,343 Common Shares outstanding. The Consolidation is intended to better position the Company for institutional investors seeking growth opportunities in the life sciences industry which the Company believes will be the main driver of shareholder value over the next two to three years.

The Company's Common Shares will begin trading on a post-consolidation basis on the CSE at market open on April 17, 2015. The Company's shares will continue to  trade under the stock symbol "MQ".  The Company has revised the record date for the Consolidation to April 21, 2015.

The Company does not intend to change its corporate name at this time, but will issue new share certificates under a new CUSIP number. Registered shareholders will receive a letter of transmittal from TMX Equity Transfer Services, the Company's transfer agent, with information on how to replace their old share certificates with the new share certificates. Brokerage firms will handle the replacement of share certificates on behalf of their shareholders’ accounts.

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative medical technologies that improve the health and quality of life for people affected by diabetes and obesity. The Company currently has exclusive rights to a family of biomedical technologies including the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics, and the temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies. The commercial development of the eMosquito and pseudobezoar technologies will require the successful coordination and execution of a wide variety of technology disciplines.

For more information contact:

Investor Relations
Phone: 604.428.0511          

info@m-pharma.ca
www.m-pharma.ca 

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the approval of the CSE regarding the Consolidation, the number of Common Shares outstanding following the Consolidation, the date of the resumption of trading on a post-Consolidation basis, and the commercialization of the eMosquito and pseudobezoar technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to obtain the approval of the CSE for the Consolidation and the failure to successfully commercialize the eMosquito and pseudobezoar technologies.

 

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.